ScripLEO Pharma A/S is not saying for certain that it has closed the door on its ointment formulation of isotretinoin, but said on 21 August the failure of TMB-001 to hit the primary endpoint in a Phase I
ScripIn a summer slowdown, biopharmaceutical start-up fundraising declined 27% in the third quarter of 2018, but Gossamer Bio Inc. and Orchard Therapeutics Ltd. brought in large venture capital rounds